A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Spira, A.; Riely, G.; Lawler, W.; Shum, M.; Socinski, M.; Yanagihara, R.; Roshan, S.; Kheoh, T.; Christensen, J.; Chao, R.; Janne, P.; Garassino, M.

authors

Publication Date

  • March 1, 2021

webpage

published in

category

keywords

  • KRAS
  • MRTX849
  • PD-1 Combination

start page

  • S695

end page

  • S696

volume

  • 16

issue

  • 3